154 related articles for article (PubMed ID: 31856912)
1. Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial.
Ma CJ; Chang TK; Tsai HL; Su WC; Huang CW; Yeh YS; Chang YT; Wang JY
Trials; 2019 Dec; 20(1):751. PubMed ID: 31856912
[TBL] [Abstract][Full Text] [Related]
2. Protocol of the QUATTRO-II study: a multicenter randomized phase II study comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as a first-line treatment in patients with metastatic colorectal cancer.
Miyo M; Kato T; Yoshino T; Yamanaka T; Bando H; Satake H; Yamazaki K; Taniguchi H; Oki E; Kotaka M; Oba K; Miyata Y; Muro K; Komatsu Y; Baba H; Tsuji A
BMC Cancer; 2020 Jul; 20(1):687. PubMed ID: 32703200
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of intravenous aflibercept with FOLFIRI in Japanese patients with previously treated metastatic colorectal cancer.
Yoshino T; Yamazaki K; Yamaguchi K; Doi T; Boku N; Machida N; Onozawa Y; Asayama M; Fujino T; Ohtsu A
Invest New Drugs; 2013 Aug; 31(4):910-7. PubMed ID: 23179335
[TBL] [Abstract][Full Text] [Related]
4. A phase-II study based on dose adjustment according to UGT1A1 polymorphism: is irinotecan underdosed in first-line FOLFIRI regimen for mCRC?
Ginzac A; Thivat E; Petorin C; Richard D; Herviou P; Molnar I; Devaud H; Creveaux I; Ferrer F; Authier N; Jary M; Pezet D; Durando X
Cancer Chemother Pharmacol; 2024 Mar; 93(3):225-236. PubMed ID: 37932443
[TBL] [Abstract][Full Text] [Related]
5. Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab in
Tsai HL; Huang CW; Chen YC; Su WC; Chang TK; Chen PJ; Li CC; Chang YT; Wang JY
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138211
[No Abstract] [Full Text] [Related]
6. Efficacy and safety of addition of bevacizumab to FOLFIRI or irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer: A meta-analysis.
Chen K; Gong Y; Zhang Q; Shen Y; Zhou T
Medicine (Baltimore); 2016 Nov; 95(46):e5221. PubMed ID: 27861344
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
Starling N; Vázquez-Mazón F; Cunningham D; Chau I; Tabernero J; Ramos FJ; Iveson TJ; Saunders MP; Aranda E; Countouriotis AM; Ruiz-Garcia A; Wei G; Tursi JM; Guillen-Ponce C; Carrato A
Ann Oncol; 2012 Jan; 23(1):119-127. PubMed ID: 21447616
[TBL] [Abstract][Full Text] [Related]
8. A Phase 1b/2a Study of GC1118 with 5-Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in Patients with Recurrent or Metastatic Colorectal Cancer.
Lee KW; Han SW; Kim TW; Ahn JB; Baek JY; Cho SH; Lee H; Kim JW; Kim JW; Kim TY; Hong YS; Beom SH; Cha Y; Choi Y; Kim S; Bang YJ
Cancer Res Treat; 2024 Apr; 56(2):590-601. PubMed ID: 38062706
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data.
Kirstein MM; Lange A; Prenzler A; Manns MP; Kubicka S; Vogel A
Oncologist; 2014 Nov; 19(11):1156-68. PubMed ID: 25326159
[TBL] [Abstract][Full Text] [Related]
10. Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting.
Ma CJ; Huang CW; Chang TK; Tsai HL; Su WC; Yeh YS; Chen PJ; Wang JY
Transl Oncol; 2019 Mar; 12(3):502-512. PubMed ID: 30594039
[TBL] [Abstract][Full Text] [Related]
11. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial.
Xu J; Xu RH; Qin S; Pan H; Bai Y; Chi Y; Wang L; Bi F; Cheng Y; Liu T; Ma D; Shen L; Ba Y; Liang J; Wang X; Yau TCC; Ma BB; Yeh KH; Lin JK; Kappeler C; Shapiro J; Kalmus J; Li J
J Gastroenterol Hepatol; 2020 Aug; 35(8):1307-1316. PubMed ID: 31900959
[TBL] [Abstract][Full Text] [Related]
12. Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.
Van Cutsem E; Martinelli E; Cascinu S; Sobrero A; Banzi M; Seitz JF; Barone C; Ychou M; Peeters M; Brenner B; Hofheinz RD; Maiello E; André T; Spallanzani A; Garcia-Carbonero R; Arriaga YE; Verma U; Grothey A; Kappeler C; Miriyala A; Kalmus J; Falcone A; Zaniboni A
Oncologist; 2019 Feb; 24(2):185-192. PubMed ID: 30190299
[TBL] [Abstract][Full Text] [Related]
13. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD).
Carrato A; Benavides M; Massutí B; Ferreiro-Monteagudo R; García Alfonso P; Falcó E; Reboredo M; Cano T; Gallego J; Viéitez JM; Layos L; Salud A; Polo E; Dotor E; Durán-Ogalla G; Rodriguez-Garrote M; Calvo A; Grande E; Aranda E
BMC Cancer; 2019 Jun; 19(1):533. PubMed ID: 31159765
[TBL] [Abstract][Full Text] [Related]
14. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients.
Shitara K; Yamanaka T; Denda T; Tsuji Y; Shinozaki K; Komatsu Y; Kobayashi Y; Furuse J; Okuda H; Asayama M; Akiyoshi K; Kagawa Y; Kato T; Oki E; Ando T; Hagiwara Y; Ohashi Y; Yoshino T
Ann Oncol; 2019 Feb; 30(2):259-265. PubMed ID: 30508156
[TBL] [Abstract][Full Text] [Related]
15. Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study.
Tabernero J; Hozak RR; Yoshino T; Cohn AL; Obermannova R; Bodoky G; Garcia-Carbonero R; Ciuleanu TE; Portnoy DC; Prausová J; Muro K; Siegel RW; Konrad RJ; Ouyang H; Melemed SA; Ferry D; Nasroulah F; Van Cutsem E
Ann Oncol; 2018 Mar; 29(3):602-609. PubMed ID: 29228087
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy.
Marks EI; Tan C; Zhang J; Zhou L; Yang Z; Scicchitano A; El-Deiry WS
Cancer Biol Ther; 2015; 16(12):1710-9. PubMed ID: 26561209
[TBL] [Abstract][Full Text] [Related]
17. Clinical Assessment of 5-Fluorouracil/Leucovorin, Nab-Paclitaxel, and Irinotecan (FOLFIRABRAX) in Untreated Patients with Gastrointestinal Cancer Using
Joshi SS; Catenacci DVT; Karrison TG; Peterson JD; Zalupski MM; Sehdev A; Wade J; Sadiq A; Picozzi VJ; Amico A; Marsh R; Kozloff MF; Polite BN; Kindler HL; Sharma MR
Clin Cancer Res; 2020 Jan; 26(1):18-24. PubMed ID: 31558477
[TBL] [Abstract][Full Text] [Related]
18. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
Strumberg D; Scheulen ME; Schultheis B; Richly H; Frost A; Büchert M; Christensen O; Jeffers M; Heinig R; Boix O; Mross K
Br J Cancer; 2012 May; 106(11):1722-7. PubMed ID: 22568966
[TBL] [Abstract][Full Text] [Related]
19. Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
Scarabel L; Garziera M; Fortuna S; Asaro F; Toffoli G; Geremia S
Sci Rep; 2020 May; 10(1):8773. PubMed ID: 32471996
[TBL] [Abstract][Full Text] [Related]
20. Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group study.
McGregor LM; Spunt SL; Furman WL; Stewart CF; Schaiquevich P; Krailo MD; Speights R; Ivy P; Adamson PC; Blaney SM
Cancer; 2009 Apr; 115(8):1765-75. PubMed ID: 19170226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
